Please login to the form below

Not currently logged in
Email:
Password:

Novimmune

This page shows the latest Novimmune news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year

myasthenic syndrome (LEMS), Novimmune’s Gamifant (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH), Regeneron/Sanofi’s Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC), and SIGA Technologies’ TPOXX (tecovirimat)

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Sosei appoints CFO Sosei appoints CFO

    Prior to this, he held the same title at several other biotech companies, including Actelion and Novimmune.

  • Novimmune appoints Guillaume de Sampaïo Novimmune appoints Guillaume de Sampaïo

    Prior to joining Novimmune he served at Danish biotech firm Forward Pharma, where he created and managed its clinical development group. ... Guillaume de Sampaïo will help us to further advance Novimmune as we move closer to the market with our lead

  • Novimmune expands senior management team Novimmune expands senior management team

    Fleurant joins Novimmune with 20 years of quality expertise in life sciences, most recently having served as head of quality affairs at Alvotech, an Icelandic biosimilars specialist. ... Eduard Holdener, chairman and chief executive of Novimmune, said:

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics